All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers DFIATIM trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F67985904%3A_____%2F25%3A00636229" target="_blank" >RIV/67985904:_____/25:00636229 - isvavai.cz</a>

  • Alternative codes found

    RIV/00023001:_____/25:00085672 RIV/00216208:11120/25:43928551 RIV/00216208:11130/25:10498417

  • Result on the web

    <a href="https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-025-04041-0" target="_blank" >https://bmcmicrobiol.biomedcentral.com/articles/10.1186/s12866-025-04041-0</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1186/s12866-025-04041-0" target="_blank" >10.1186/s12866-025-04041-0</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    The effect of the administration form of antibiotic therapy on the gut microbiome in patients with infected diabetic foot ulcers DFIATIM trial

  • Original language description

    Background Diabetic foot infections (DFIs) contribute to the global disability burden. Beta-lactams are the most commonly used antibiotics for treating DFIs. However, the use of antibiotics may lead to disruption of the healthy balance of the gut microbiota, causing dysbiosis. Methods Patients with infected diabetic foot ulcers (iDFUs) were treated with two kinds of beta-lactams (amoxicillin/clavulanic acid or ceftazidime) according to microbial sensitivity of causative agents via bolus or continuous administration modes. Changes in the gut microbiome of patients were analyzed. Diabetic patients without iDFUs were used as a control group. 16 S ribosomal RNA gene amplicon sequencing was performed on stool samples collected from participants.ResultsAlpha diversity and beta diversity of gut microbiota of treated patients did not show significant differences between bolus and continuous modes. However, significant differences were observed between gut microbiota diversity of treated patients and control group. PCoA plots showed individualized responses of the patient's gut microbiota to antibiotics at different times using both administration forms associated with the pre-treatment state of microbiota composition. Enterococcus, Sellimonas, and Lachnoclostridium were the common bacterial markers differentially abundant in the gut microbiota of antibiotic-treated patients with iDFUs while Roseburia, Dorea, and Monoglobus were mainly abundant in the gut microbiota of patients without iDFUs. Predicted pathways like Transporters, ABC transporters and Phosphotranspherase system (PTS) were upregulated in the gut microbiome of patients treated with bolus regime which may lead to increased intestinal barrier permeability. Conclusion The present study reported alterations in gut microbiota composition and functionality and provided the bacterial markers as well as potential metabolic signatures associated with each administration mode in patients with iDFUs, which may be used as a reference set for future studies of the effect of antibiotics administration on the gut microbiome of patients with iDFUs. This study shed light on the importance of understanding the effect of antibiotic administration form on gut microbiome in patients with iDFUs.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    10606 - Microbiology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2025

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    BMC Microbiology

  • ISSN

    1471-2180

  • e-ISSN

    1471-2180

  • Volume of the periodical

    25

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    GB - UNITED KINGDOM

  • Number of pages

    15

  • Pages from-to

    339

  • UT code for WoS article

    001498532600002

  • EID of the result in the Scopus database

    2-s2.0-105006833935